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Background
Cyclic guanosine monophosphate (cGMP) is a key second-
ary messenger that is produced in response to nitric oxide.
One of the key mediators of cGMP signaling, cGMP-
dependent protein kinase (PKG), is activated upon binding
to cGMP and phosphorylates downstream substrates in a
process required for important physiological processes
such as vasodilation, nociception, and memory formation.
PKGs are also known to mediate most effects of drugs
that increase cellular cGMP levels, including nitric oxide-
releasing agents and phosphodiesterase inhibitors, which
are used for the treatment of angina pectoris and erectile
dysfunction, respectively. It is known that PKG is prefer-
entially activated by cGMP over cAMP roughly 60-100
fold – however, the molecular mechanism by which
cGMP is distinguished from a structurally similar messen-
ger, cAMP, is poorly defined. Using competition fluores-
cence polarization (FP), X-ray crystallography, and in vitro
kinase assays, we sought to understand the molecular
basis for cGMP selectivity in PKGI.
Results
We determined using competition FP that the C-terminal
cGMP-binding domain (CNB-B) is a minimal construct
that has 200-fold selectivity for cGMP. Using X-ray crys-
tallography, we solved the structures of CNB-B bound to
cGMP (1.65 Å) and in the apo form (2.0Å). The CNB-B:
cGMP complex structure reveals that highly conserved
residues om strand beta 5 and the C-helix of PKGIb
interact specifically with the guanine moiety through
hydrogen bonding and π stacking interactions, providing
over 240-folds cGMP selectivity. Mutagenesis of these
residues demonstrates their importance not only in
cGMP selectivity, but also in activation. Surprisingly,
comparison with the apo structure reveals that the
pocket is not preformed, but assembled through major
structural rearrangements of the helical domain.
Our affinity measurements demonstrate that CNB-B is a
minimal domain that provides cGMP selectivity for PKG
I, while our X-ray structures of CNB-B reveal contacts
unique to PKG that confer cGMP selectivity. Furthermore,
kinase assays show that these contacts play a role in
cGMP-dependent activation of the full-length protein.
Conclusion
Taken together, our data suggest that PKGI has a unique
mode of recognition for cGMP and describes conforma-
tional changes required for activation of the full-length
kinase.
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